Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gallium 68 tilmanocept - Navidea Biopharmaceuticals

Drug Profile

Gallium 68 tilmanocept - Navidea Biopharmaceuticals

Alternative Names: [68Ga]Ga-tilmanocept; Ga-68 tilmanocept; Gallium 68 labelled tilmanocept - Navidea Biopharmaceuticals

Latest Information Update: 28 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Navidea Biopharmaceuticals; University of Alabama at Birmingham
  • Developer Navidea Biopharmaceuticals; University Medical Center Utrecht; University of Alabama at Birmingham
  • Class Imaging agents; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Thyroid cancer
  • No development reported Atherosclerosis

Most Recent Events

  • 28 Sep 2023 No recent reports of development identified for preclinical development in Atherosclerosis(Diagnosis) in USA
  • 19 Apr 2022 Navidea Biopharmaceuticals receives a decision of grant for patent application covering targeted delivery of payloads attached to the Manocept platform in Japan
  • 29 Nov 2021 Phase-III clinical trials in Thyroid cancer (Diagnosis) in Netherlands (Intratumoural) (EudraCT2021-002470-42)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top